This task order is to manufacture sterile bulk product TLC-ART101 (2 l) in full compliance with cgmp regulations. TLC-art 101 (targeted long-acting combination anti-retroviral therapy 101) is a…
Ended Awarded Last action
- Contract number
- 75N93020F00001
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,080,409
Award facts
- Contract value 100% obligated
- $1,080,409.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Menlo Park, CA 94025, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $294,778 | |
| Original award | $785,631 |
About this award
This task order is for Sri International to manufacture the sterile bulk product TLC-ART101 (2 liters) in full compliance with current good manufacturing practice regulations. TLC-ART101 is a targeted long-acting combination antiretroviral therapy consisting of the antiretrovirals lopinavir, ritonavir, and a third undisclosed antiretroviral. The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services National Institutes of Health, issued this $1.08 million cost-plus-fixed-fee delivery order to support formulation development and clinical manufacturing of TLC-ART101. Sri International will perform the work at its facility located in West Menlo Park, California through December 2021.
Description
This task order is to manufacture sterile bulk product TLC-ART101 (2 l) in full compliance with cgmp regulations. TLC-art 101 (targeted long-acting combination anti-retroviral therapy 101) is a preparation of three antiretrovirals lopinavir, ritonavi
Quick answers
Who was awarded contract 75N93020F00001?
75N93020F00001 was awarded to Sri International by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 15, 2020.
How much is contract 75N93020F00001 worth?
The government has obligated $1,080,409 on 75N93020F00001.
Is contract 75N93020F00001 an order under another contract?
Yes. 75N93020F00001 is a delivery order under HHSN272201400006I, an indefinite delivery contract.
Was contract 75N93020F00001 competed?
The extent of competition for 75N93020F00001 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award